Worldwide, there have been more than 11.4 million cases, and over 534,000
deaths attributed to COVID-19. According to the World Health Organization
(WHO), member nations recorded at least 212,000 new COVID-19 cases on July
4, the highest single-day total increase since the beginning of the pandemic.
WHO has accepted the recommendation from the Solidarity Trial’s
International Steering Committee to discontinue the trial’s hydroxychloroquine
and lopinavir/ritonavir treatment arms for COVID-19. The International Steering
Committee formulated the recommendation in light of the evidence for
hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standardof-care from the Solidarity trial interim results, and from a review of the
evidence from all trials presented at the 1-2 July WHO Summit on COVID-19
research and innovation. These interim trial results show that
hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the
mortality of hospitalized COVID-19 patients when compared to standard of
care. Solidarity trial investigators will interrupt the trials with immediate effect.
This decision applies only to the conduct of the Solidarity trial in hospitalized
patients and does not affect the possible evaluation in other studies of
hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as preor post-exposure prophylaxis for COVID-19. The interim Solidarity results are now
being readied for peer-reviewed publication.
Indonesia’s Health Ministry has announced last July 5 that 82 people died of
COVID-19, the highest reported death toll in a day so far since the outbreak in
the country started, bringing the official death toll up to 3,171. East Java
remains the province with the highest number of COVID-19 deaths with 1,020
deaths. With 63,749 confirmed COVID-19 cases and a total of 3,171 deaths as
of July 5, Indonesia remains the country with the highest number of COVID-19
cases and the highest death toll among ASEAN Member States